Literature DB >> 1742647

Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo.

C G Peterson1, I Enander, J Nystrand, A S Anderson, L Nilsson, P Venge.   

Abstract

A radioimmunoassay was developed allowing measurement of the cytotoxic cationic ECP. The assay, which has a total incubation time of 3.5 hr, is a double antibody assay with radiolabelled ECP, covering the concentration range of 2-200 micrograms/l. Performance data show a detection limit of less than 2 micrograms/l and a cross-reactivity with eosinophil protein X (EPX/EDN) of less than 0.06%. The coefficient of variation (%) within the measuring range was, within assay 4.8-10.4, and total 6.6-12.0. The assay is useful for measurement in various body fluids including serum, nasal secretions and bronchoalveolar lavage fluid, and dilution of samples prior to analysis was generally not required. Sera from 100 apparently healthy individuals revealed a geometric mean of 6.0 micrograms ECP/l and a range (95%) of 2.3-15.9 micrograms/l. The elimination rate of ECP, t1/2, in vivo was estimated to be 65 min when ECP was measured in serum. Comparisons between this assay and a method previously described showed that the new method is superior with regard to precision and assay procedure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742647     DOI: 10.1111/j.1365-2222.1991.tb00847.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  20 in total

1.  Immunological responses to respiratory syncytial virus infection in infancy.

Authors:  R L Smyth; J N Fletcher; H M Thomas; C A Hart
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

2.  A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide.

Authors:  C Heuck; L Heickendorff; O D Wolthers
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

3.  Relationship between disease severity and inflammatory markers in cystic fibrosis.

Authors:  D Y Koller; M Götz; C Wojnarowski; I Eichler
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

4.  An extragranular compartment of blood eosinophils contains eosinophil protein X/eosinophil-derived neurotoxin (EPX/EDN).

Authors:  Malgorzata Karawajczyk; Christer G B Peterson; Per Venge; Rodolfo C Garcia
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

5.  Effects of inhaled steroid treatment on serum eosinophilic cationic protein (ECP) and low affinity receptor for IgE (Fc epsilon RII/sCD23) in childhood bronchial asthma.

Authors:  I Türktaş; S Demirsoy; E Koç; N Gökçora; S Elbeg
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

6.  A field study on clinical signs and symptoms in cleaners at floor polish removal and application in a Swedish hospital.

Authors:  Gunilla Wieslander; Dan Norbäck
Journal:  Int Arch Occup Environ Health       Date:  2010-04-21       Impact factor: 3.015

7.  Release of eosinophil cationic protein (ECP) in anaphylactoid anaesthetic reactions in vivo and in vitro.

Authors:  E S Assem
Journal:  Agents Actions       Date:  1994-06

8.  Atopy, symptoms and indoor environmental perceptions, tear film stability, nasal patency and lavage biomarkers in university staff.

Authors:  Jan Vilhelm Bakke; Gunilla Wieslander; Dan Norbäck; Bente E Moen
Journal:  Int Arch Occup Environ Health       Date:  2007-12-08       Impact factor: 3.015

9.  Serum eosinophilic cationic protein may predict clinical course of wheezing in young children.

Authors:  J R Villa; G García; S Rueda; A Nogales
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

10.  Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins.

Authors:  Michelle A Makiya; Jesica A Herrick; Paneez Khoury; Calman P Prussin; Thomas B Nutman; Amy D Klion
Journal:  J Immunol Methods       Date:  2014-06-08       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.